{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:48:04Z","timestamp":1767340084658,"version":"3.41.0"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Immunodeficiency-associated lymphoproliferative disorders (IA-LPDs) constitute a diverse range of conditions including posttransplant lymphoproliferative disorders, other iatrogenic IA-LPDs, and lymphoproliferative disorders associated with an underlying primary immune disorder or HIV infection. IA-LPDs are clinically and pathologically heterogeneous, and there is a lack of standardization of diagnostic terminology. They can represent a potential serious diagnostic pitfall because the histological features of clinically indolent proliferations may mimic those of high-grade lymphoma. However, correct identification of these entities is essential given that complete remission may occur upon reversal of the underlying cause of immunosuppression without the need for systemic therapy. IA-LPDs presenting in the skin are rare but well documented. One form of iatrogenic IA-LPD, methotrexate-associated lymphoproliferative disorder (MTX-LPD), can present with cutaneous nodules, plaques, or ulcers. Predominantly, MTX-LPD develops in the context of long-term treatment of autoimmune conditions, such as rheumatoid arthritis, dermatomyositis, and Sj\u00f6gren syndrome, and may be associated with underlying Epstein\u2013Barr virus (EBV) infection. We present 4 cases of cutaneous EBV-positive B-cell MTX-LPD and describe their clinical and morphological findings. Comparison of our histological findings to the diagnostic criteria for EBV-positive mucocutaneous ulcer (EBVMCU) revealed significant overlap, highlighting the intersection between MTX-LPD and EBVMCU. Withdrawal of methotrexate resulted in healing of all lesions at a mean time of 2 months. In summary, close clinicopathological correlation is vital to identify MTX-LPD presenting as cutaneous EBVMCU given that the initial treatment strategy is that of withdrawal of methotrexate without the need for immediate systemic therapy.<\/jats:p>","DOI":"10.1097\/dad.0000000000002419","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T11:04:50Z","timestamp":1689678290000},"page":"519-531","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Skin-Limited, Methotrexate-Associated Epstein\u2013Barr Virus\u2013Positive Mucocutaneous Ulcer\u2014A Mimicker of High-Grade Lymphoma. A Report of 4 Cases and Review of the Literature"],"prefix":"10.1097","volume":"45","author":[{"given":"Philip S.","family":"Macklin","sequence":"first","affiliation":[{"name":"Doctor, Department of Cellular Pathology, Oxford University Hospitals, NHS Foundation Trust, Oxford, Oxfordshire, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Fisher","sequence":"additional","affiliation":[{"name":"Doctor, Department of Dermatology, Royal Berkshire, NHS Foundation Trust, Reading, Berkshire, United Kingdom; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Stonard","sequence":"additional","affiliation":[{"name":"Doctor, Department of Cellular Pathology, Oxford University Hospitals, NHS Foundation Trust, Oxford, Oxfordshire, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rubeta N.","family":"Matin","sequence":"additional","affiliation":[{"name":"Doctor, Department of Dermatology, Oxford University Hospitals, NHS Foundation Trust, Oxford, Oxfordshire, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Ieremia","sequence":"additional","affiliation":[{"name":"Doctor, Department of Cellular Pathology, Oxford University Hospitals, NHS Foundation Trust, Oxford, Oxfordshire, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-20250616","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.blre.2008.03.009","article-title":"Immunodeficiency-associated lymphomas","volume":"22","author":"Tran","year":"2008","journal-title":"Blood Rev."},{"key":"R3-20250616","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/PAS.0000000000000225","article-title":"Methotrexate-associated B-cell lymphoproliferative disorders presenting in the skin: a clinicopathologic and immunophenotypical study of 10 cases","volume":"38","author":"Koens","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R4-20250616","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1200\/JCO.1996.14.6.1943","article-title":"Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases","volume":"14","author":"Salloum","year":"1996","journal-title":"J Clin Oncol"},{"key":"R5-20250616","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-008-9069-8","article-title":"Spontaneous remission of \u201cmethotrexate-associated lymphoproliferative disorders\u201d after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature","volume":"26","author":"Rizzi","year":"2009","journal-title":"Med Oncol."},{"key":"R6-20250616","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/PAS.0b013e3181cf8622","article-title":"EBV positive mucocutaneous ulcer\u2014a study of 26 cases associated with various sources of immunosuppression","volume":"34","author":"Dojcinov","year":"2010","journal-title":"Am J Surg Pathol."},{"key":"R7-20250616","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/j.clml.2018.10.003","article-title":"Epstein-barr virus-positive mucocutaneous ulcer: case report and review of the first 100 published cases","volume":"19","author":"Sinit","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"R8-20250616","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.3390\/ijms22031053","article-title":"Epstein-barr virus-positive mucocutaneous ulcer: a unique and curious disease entity","volume":"22","author":"Ikeda","year":"2021","journal-title":"Int J Mol Sci."},{"key":"R10-20250616","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1182\/blood-2018-04-842559","article-title":"Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal?","volume":"132","author":"Natkunam","year":"2018","journal-title":"Blood"},{"key":"R11-20250616","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"R12-20250616","first-page":"1741","article-title":"Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate","volume":"18","author":"Ellman","year":"1991","journal-title":"J Rheumatol."},{"key":"R13-20250616","first-page":"322","article-title":"Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication","volume":"34","author":"Hoshida","year":"2007","journal-title":"J Rheumatol."},{"key":"R14-20250616","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199305063281806","article-title":"Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis","volume":"328","author":"Kamel","year":"1993","journal-title":"N Engl J Med."},{"key":"R15-20250616","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1046\/j.1365-2133.1996.d01-946.x","article-title":"Reversible cutaneous lymphoma occurring during methotrexate therapy","volume":"135","author":"Viraben","year":"1996","journal-title":"Br J Dermatol."},{"key":"R16-20250616","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1600-0560.1999.tb01837.x","article-title":"Epstein Barr virus-associated lymphoproliferative-disorders primarily involving the skin","volume":"26","author":"Chai","year":"1999","journal-title":"J Cutan Pathol."},{"key":"R17-20250616","first-page":"1546","article-title":"Primary cutaneous B cell lymphoma during methotrexate therapy for rheumatoid arthritis","volume":"27","author":"Fam","year":"2000","journal-title":"J Rheumatol."},{"key":"R18-20250616","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0025-6196(11)63231-X","article-title":"Cutaneous lymphoma associated with Epstein-Barr virus infection in 2 patients treated with methotrexate","volume":"76","author":"Tournadre","year":"2001","journal-title":"Mayo Clinic Proc."},{"key":"R19-20250616","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.0303-6987.2005.00363.x","article-title":"Epstein--Barr virus-associated B-cell lymphoma in the setting of iatrogenic immune dysregulation presenting initially in the skin","volume":"32","author":"Verma","year":"2005","journal-title":"J Cutan Pathol."},{"key":"R20-20250616","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jaad.2006.09.011","article-title":"Methotrexate-associated lymphoproliferative disorder in a patient with rheumatoid arthritis presenting in the skin","volume":"56","author":"Clarke","year":"2007","journal-title":"J Am Acad Dermatol."},{"key":"R21-20250616","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.jaad.2005.09.015","article-title":"Reversal of multifocal cutaneous lymphoproliferative disease associated with Epstein-Barr virus after withdrawal of methotrexate therapy for rheumatoid arthritis","volume":"57","author":"Maruani","year":"2007","journal-title":"J Am Acad Dermatol."},{"key":"R22-20250616","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jaad.2008.10.051","article-title":"Methotrexate-related lymphoproliferative disorder with extensive vascular involvement in a patient with rheumatoid arthritis","volume":"61","author":"Shimura","year":"2009","journal-title":"J Am Acad Dermatol."},{"key":"R23-20250616","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2230.2009.03293.x","article-title":"Methotrexate-induced primary cutaneous diffuse large B-cell lymphoma with an \u2018angiocentric\u2019 histological morphology","volume":"35","author":"Pfistershammer","year":"2010","journal-title":"Clin Exp Dermatol."},{"key":"R24-20250616","doi-asserted-by":"crossref","first-page":"e717","DOI":"10.1200\/JCO.2010.28.3796","article-title":"Primary cutaneous Epstein-Barr virus-associated B-cell lymphoma arising at the site of subcutaneous injections of methotrexate","volume":"28","author":"Giard","year":"2010","journal-title":"J Clin Oncol."},{"key":"R25-20250616","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1600-0463.2012.02939.x","article-title":"EBV+ cutaneous B-cell lymphoproliferation of the leg in an elderly patient with mycosis fungoides and methotrexate treatment","volume":"121","author":"Rausch","year":"2013","journal-title":"APMIS"},{"key":"R26-20250616","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1684\/ejd.2013.2044","article-title":"Methotrexate-associated lymphoproliferative disorder mimicking ecthyma gangrenosum in a patient with rheumatoid arthritis","volume":"23","author":"Inuzuka","year":"2013","journal-title":"Eur J Dermatol."},{"key":"R27-20250616","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3899\/jrheum.130270","article-title":"A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders","volume":"41","author":"Yamakawa","year":"2014","journal-title":"J Rheumatol."},{"key":"R28-20250616","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2169\/internalmedicine.53.1735","article-title":"Rheumatoid arthritis\/methotrexate-associated primary cutaneous diffuse large B-cell lymphoma, leg type","volume":"53","author":"Matsumoto","year":"2014","journal-title":"Intern Med."},{"key":"R29-20250616","doi-asserted-by":"crossref","first-page":"366","DOI":"10.2340\/00015555-1951","article-title":"Cutaneous manifestations of methotrexate-associated lymphoproliferative disorders: report of two cases and a review of the literature","volume":"95","author":"Shimizu","year":"2015","journal-title":"Acta Dermato Venereologica"},{"key":"R30-20250616","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3109\/10428194.2015.1049165","article-title":"Methotrexate-associated EBV-positive CD20-negative diffuse large B-cell lymphoma localized to skin presenting as multiple chronic lower leg ulcers","volume":"57","author":"McKelvie","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"R31-20250616","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamadermatol.2017.6062","article-title":"Methotrexate-associated B-cell lymphoproliferative disease in a patient with cutaneous T-cell lymphoma","volume":"154","author":"Maderal","year":"2018","journal-title":"JAMA Dermatol."},{"key":"R32-20250616","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/ced.13660","article-title":"Methotrexate-associated lymphoproliferative disorder presenting as giant ulcers on the leg","volume":"43","author":"Oka","year":"2018","journal-title":"Clin Exp Dermatol."},{"key":"R33-20250616","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/DAD.0000000000001301","article-title":"A case of methotrexate-associated lymphoproliferative disorder (lymphomatoid granulomatosis) of the skin","volume":"41","author":"Nishida","year":"2019","journal-title":"The Am J Dermatopathology"},{"key":"R34-20250616","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.pathol.2020.10.019","article-title":"Primary cutaneous methotrexate-associated B-cell lymphoproliferative disorders other than EBV-positive mucocutaneous ulcer: clinical, pathological, and immunophenotypic features","volume":"53","author":"Satou","year":"2021","journal-title":"Pathology"},{"key":"R35-20250616","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/his.13464","article-title":"Comparison of Epstein-Barr virus-positive mucocutaneous ulcer associated with treated lymphoma or methotrexate in Japan","volume":"72","author":"Daroontum","year":"2018","journal-title":"Histopathology"},{"key":"R36-20250616","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/rheumatology\/kez393","article-title":"EBV-positive mucocutaneous ulcer in a patient with systemic lupus erythematosus","volume":"59","author":"Ritter","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R37-20250616","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1038\/s41379-020-0599-8","article-title":"Clinicopathological analysis of 34 Japanese patients with EBV-positive mucocutaneous ulcer","volume":"33","author":"Ikeda","year":"2020","journal-title":"Mod Pathol."},{"key":"R38-20250616","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1002\/ski2.108","article-title":"A case of methotrexate-associated Epstein-Barr virus-positive mucocutaneous ulcer","volume":"2","author":"Sakamoto","year":"2022","journal-title":"Skin Health Dis."},{"key":"R39-20250616","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1080\/10428190600799961","article-title":"Methotrexate-induced lymphoproliferative disorder in a patient with Sezary syndrome","volume":"47","author":"Rodrigues","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"R40-20250616","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1600-0560.2009.01459.x","article-title":"Transient iatrogenic immunodeficiency-related B-cell lymphoproliferative disorder of the skin in a patient with mycosis fungoides\/Sezary syndrome","volume":"38","author":"Curry","year":"2011","journal-title":"J Cutan Pathol."},{"key":"R41-20250616","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bjd.14602","article-title":"Epstein-Barr virus-associated B-cell lymphoproliferative disorder in a patient with Sezary syndrome treated by methotrexate","volume":"175","author":"Ingen-Housz-Oro","year":"2016","journal-title":"Br J Dermatol."},{"key":"R42-20250616","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1097\/MPH.0000000000000709","article-title":"Epstein-barr virus-associated mucocutaneous ulcer in a patient with T-cell acute lymphoblastic leukemia: importance of accurate diagnosis and conservative management","volume":"39","author":"Vatsayan","year":"2017","journal-title":"J Pediatr Hematol\/Oncol"},{"key":"R43-20250616","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jdcr.2018.10.013","article-title":"EBV(+) mucocutaneous ulcers in the setting of pre-existing cutaneous T-cell lymphoproliferative disorders: a report of 2 cases","volume":"5","author":"Craddock","year":"2019","journal-title":"JAAD Case Rep."},{"key":"R44-20250616","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1038\/emm.2014.82","article-title":"EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management","volume":"47","author":"Ok","year":"2015","journal-title":"Exp Mol Med."},{"key":"R45-20250616","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc.2016.92","article-title":"Epstein-Barr virus: more than 50 years old and still providing surprises","volume":"16","author":"Young","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"R46-20250616","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/path.1711680311","article-title":"High incidence of EBV genome in CD30-positive non-Hodgkin's lymphomas","volume":"168","author":"Kanavaros","year":"1992","journal-title":"J Pathol."},{"key":"R47-20250616","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0190-9622(84)70259-3","article-title":"Two patterns of skin ulceration induced by methotrexate in patients with psoriasis","volume":"11","author":"Lawrence","year":"1984","journal-title":"J Am Acad Dermatol."},{"key":"R48-20250616","first-page":"450","article-title":"Cutaneous ulceration as a sign of methotrexate toxicity","volume":"11","author":"Del Pozo","year":"2001","journal-title":"Eur J Dermatol."},{"key":"R49-20250616","doi-asserted-by":"crossref","first-page":"S197","DOI":"10.1067\/mjd.2003.388","article-title":"Cutaneous ulceration caused by methotrexate","volume":"49","author":"Kazlow","year":"2003","journal-title":"J Am Acad Dermatol."},{"key":"R50-20250616","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/sj.bdj.4811972","article-title":"Methotrexate and oral ulceration","volume":"198","author":"Deeming","year":"2005","journal-title":"Br Dent J."},{"key":"R51-20250616","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.tripleo.2004.08.020","article-title":"Oral effects of low-dose methotrexate treatment","volume":"100","author":"Kalantzis","year":"2005","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endodontology"},{"key":"R52-20250616","first-page":"413","article-title":"Mucocutaneous ulcerations secondary to methotrexate","volume":"81","author":"Warner","year":"2008","journal-title":"Cutis"},{"key":"R53-20250616","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0001-7310(09)70233-9","article-title":"Methotrexate-associated lymphoproliferative disorder presenting as oral ulcers in a patient with rheumatoid arthritis [Article in Spanish]","volume":"100","author":"Pastor-Nieto","year":"2009","journal-title":"Actas Dermo-Sifiliogr"},{"key":"R54-20250616","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ajcp\/aqw214","article-title":"EBV-positive B-cell proliferations of varied malignant potential: 2015 SH\/EAHP workshop report-Part 1","volume":"147","author":"Natkunam","year":"2017","journal-title":"Am J Clin Pathol."},{"key":"R55-20250616","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40164-016-0042-5","article-title":"Diagnostic and therapeutic challenges of EBV-positive mucocutaneous ulcer: a case report and systematic review of the literature","volume":"5","author":"Roberts","year":"2015","journal-title":"Exp Hematol Oncol."},{"key":"R56-20250616","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/DAD.0000000000001930","article-title":"Systemic EBV-positive methotrexate-related lymphoproliferative disorder associated with skin lesion resembling EBV-positive mucocutaneous ulcer: a report of two cases","volume":"43","author":"Fujimoto","year":"2021","journal-title":"Am J Dermatopathol"},{"key":"R57-20250616","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1097\/PAS.0000000000000282","article-title":"EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder","volume":"38","author":"Hart","year":"2014","journal-title":"Am J Surg Pathol."},{"key":"R58-20250616","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/PAS.0000000000001186","article-title":"The spectrum of EBV-positive mucocutaneous ulcer: a study of 9 cases","volume":"43","author":"Prieto-Torres","year":"2019","journal-title":"Am J Surg Pathol."},{"key":"R59-20250616","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/PAS.0000000000001661","article-title":"EBV-Positive mucocutaneous ulcer with small lymphocytic infiltration mimicking nonspecific ulceration","volume":"45","author":"Fujimoto","year":"2021","journal-title":"Am J Surg Pathol."},{"key":"R60-20250616","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/imj.13219","article-title":"Fatal outcome of an Epstein-Barr virus positive mucocutaneous ulcer secondary to methotrexate","volume":"46","author":"Nakauyaca","year":"2016","journal-title":"Intern Med J."}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000002419","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T18:01:25Z","timestamp":1750096885000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000002419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":58,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000002419","relation":{},"ISSN":["0193-1091"],"issn-type":[{"type":"print","value":"0193-1091"}],"subject":[],"published":{"date-parts":[[2023,8]]}}}